Can Intensive Insulin Therapy Improve Outcomes of COVID-19 Patients

• Status: Completed
• Trial end date: 2021-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Evaluation of the reciprocal relation between hyperglycemia/diabetes mellitus (HG/DM) and COVID-19 disease and the effect of mode of insulin therapy; intensive (IIT) or conventional (CIT) on patients' outcomes All patients admitted to the quarantine hospitals with mild-severe COVID disease were evaluated using the COVID-GRAM Critical Illness Risk Score and gave blood samples for estimation of random blood glucose. Diabetic patients and non-diabetic patients with persistent HG were randomly divided according to mode of IT. Patients who were free HG were included as control normoglycemic (NG) patients. Study outcomes included the incidence of progress to critical illness and mortality rate (MR), and the effect of IT on such outcomes

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Benha University
• Treatments: Insulin; Insulin, Globin Zinc

Criteria

Inclusion Criteria:

Diabetic Non-diabetic Confirmed COVID-19 disease both by PCR diagnosis of viral RNA and by CT diagnosis of COVID-associated pneumonia.

Exclusion Criteria:

Patients younger than 18 years, patients admitted with critical illness requiring immediate admission to ICU, patients deceased before evaluation, patients who had autoimmune diseases or were maintained on immunosuppressive therapy, patients with chronic medical diseases other than DM, patients requiring surgical interference for emergency conditions, and patients who had cancer or were maintained anticancer therapy were excluded from the study.